Oncofinder: a novel platform for screening benignant nevi from melanomas based on lipid phenotype using mass spectrometry and machine learning

Oncofinder is a Research-Use Only (RUO) platform that is being developed for the diagnosis, staging and prognosis of melanoma using the lipid fingerprints acquired from tissue or liquid biopsies. A panel of lipid biomarkers allows the rapid and accurate screening of benignant nevi from melanomas by studying the lipid fingerprint using mass spectrometry and artificial intelligence. This technology circumvents the limitations inherent to current methodologies, based on dermoscopic, histopathological and surrogate biomarkers, reducing the laboratory work and providing a faster and easier diagnosis. Moreover, the specificity of the lipid biomarkers together with the power of mass spectrometry and machine learning confer to the Oncofinder platform strong prognostic capabilities not only to detect melanoma but also to determinate their malignant potential. However, the high complexity, size and cost of the mass spectrometers limits its implementation in anatomic pathology analytical services. In this work, we evaluate a prototype dual polarity linear benchtop MALDITOF mass spectrometer (Shimadzu) for the generation of the lipid profiles. A preliminary screening of a collection of human biopsies of nevi and melanomas demonstrated a high potential for screening melanoma from benignant biopsies with a sensitivity near 100% with a representative collection of samples.

Content Type:
Document Number:
ASMS 2020 - WP 399
Product Type:
Life Science, MALDI-TOF Mass Spectrometry
Pharma & Biopharma, Life Science Solutions, MALDI-8020 Benchtop Linear MALDI-TOF Mass Spectrometer
File Name:
File Size:

View Article Question about this literature?

Top of This Page